Clinical Trials
24 trialsNCT05355701 2026-05-14
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT06544655 2026-04-17
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT05891171 2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT00266279 2020-09-03
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
University of Louisville
Phase 2 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT00256308 2018-05-01
Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer
University of California, Irvine
Phase 2 Terminated
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00101075 2017-02-27
Title XELOX FOR SALIVARY GLAND CANCERS
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00256295 2017-02-01
Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
University of California, Irvine
Phase 2 Terminated
NCT00448552 2016-12-15
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
University of Miami
Phase 2 Completed
NCT00439426 2016-11-02
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT01403259 2014-08-20
SOX as Salvage Treatment in Nasopharyngeal Carcinoma
Fudan University
Phase 2 Terminated
NCT00415298 2014-01-10
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT01370876 2013-12-10
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
Nang Kuang Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00557206 2013-11-05
Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
Minneapolis Veterans Affairs Medical Center
Phase 2 Terminated
NCT00091182 2013-06-05
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Phase 2 Completed
NCT00101270 2013-06-05
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005035 2013-01-31
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00503997 2012-05-10
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00363831 2010-07-28
Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma
The University of Hong Kong
Phase 2 Unknown
NCT00436800 2009-09-18
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Sanofi
Phase 2 Completed
NCT00611754 2008-02-11
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sanofi
Phase 2 Completed